Abstract 1215P
Background
NGS techniques can detect molecular alterations in cell-free DNA (cfDNA) isolated from plasma samples for biomarker discovery, diagnostics, and disease monitoring. We previously reported a 0.2% variant allele frequency (VAF) limit of detection (LOD) for single nucleotide variants (SNVs) and insertions and deletions (indels) with 98% and 99% accuracies and 91% and 83% sensitivities, respectively, for our cfDNA assay. To assess the clinical application of the cfDNA liquid biopsy, we compared findings with tumor-based NGS assays, including whole exome sequencing (WES) and RNA-seq.
Methods
A panel of 216 clinically actionable genes, including exonic and intronic regions, was used in the cfDNA assay. Commercial references and human cell lines were used for analytical validation. Our variant calling pipeline was used to analyze sequenced samples. WES, RNA-seq, and cfDNA analysis were performed on 65 matched patient samples. Gene fusions in cfDNA were validated with tumor RNA-seq data.
Results
Intersection was observed between traditional WES analysis and the developed liquid biopsy assay for 35.3% (23/65) patients. WES results were concordant with the cfDNA assay for a subset of mutations from the targeted gene panel for SNVs (sensitivity = 0.23) and indels (sensitivity = 0.29); for clinically actionable mutations, we observed a slightly stronger relationship (sensitivity = 0.35). The cfDNA assay identified an additional 66.2% and 31.4% SNVs and indels, respectively, within the clinically actionable gene panel compared to WES. With a LOD of 0.5% VAF, 95% sensitivity was observed for genomic fusion calling. The cfDNA assay detected clinically actionable fusion genes, such as EWSR1–ATF1.
Conclusions
While our WES and cfDNA analyses had low concordance, previous reports noted discordance in tumor DNA and cfDNA analyses due to tumor heterogeneity and other biological factors, such as cfDNA half-life and variations in shedding among clones. Our cfDNA panel also included genes from intronic regions and detected additional alterations not found by WES. These findings highlight the potential for this newly developed cfDNA assay to be used to guide clinical decision making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
BostonGene, Corp.
Funding
BostonGene, Corp.
Disclosure
A. Yudina, S. Starikov, A. Efremov, D. Sookiasian, E. Nuzhdina, M. Chasse, T. Conroy, N. English, A. Love, D. Tabakov, A. Baisangurov, C. Tazearslan: Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Personal, Stocks/Shares: BostonGene, Corp. S. Podsvirova: Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. N. Fowler: Financial Interests, Personal, Officer: BostonGene, Corp.; Financial Interests, Personal, Stocks/Shares: BostonGene, Corp.; Financial Interests, Personal, Leadership Role: BostonGene, Corp.; Financial Interests, Personal and Institutional, Research Funding: Celgene, Gilead, Roche; Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: Celgene, Gilead, Roche; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. A. Bagaev: Financial Interests, Personal, Leadership Role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Personal, Stocks/Shares: BostonGene, Corp.
Resources from the same session
1230P - hPG80 (circulating progastrin) is a new blood-based biomarker for diagnosis of early-stage non-small cell lung cancers
Presenter: Paul Hofman
Session: Poster session 14
1231P - Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer
Presenter: Yeji Jung
Session: Poster session 14
1232P - Analytic analysis of PanSeer7, a targeted bisulfite sequencing assay for blood-based multi-cancer detection for cancer early detection and tissue-of-origin identification
Presenter: Xinrong Yang
Session: Poster session 14
1233P - Accurate prediction of gastrointestinal cancer tissue of origin using comprehensive plasma cell-free DNA fragmentomics features
Presenter: Xinrong Yang
Session: Poster session 14
1234P - HistoMate: Automated preprocessing software for digital histopathology image to enhance deep learning
Presenter: Jinok Lee
Session: Poster session 14
1235P - Enrichment of rare cancers in pragmatic precision cancer medicine trial: Experience from IMPRESS-Norway
Presenter: Aaslaug Helland
Session: Poster session 14
1236P - Feasibility of online symptom monitoring to detect lung cancer relapse in Poland
Presenter: Ewa Pawlowska
Session: Poster session 14
1237P - Design and validation of a custom next-generation sequencing panel in melanoma, glioma and gastrointestinal stromal tumor
Presenter: Xiaoyan Zhou
Session: Poster session 14
1238P - Detecting driver mutations by AmoyDx 11-gene PCR with high concordance with next-generation sequencing in Chinese non-small cell lung cancer patients
Presenter: Dongmei Lin
Session: Poster session 14
1239P - NHS-Galleri trial enrolment approaches and participant sociodemographic diversity
Presenter: Charles Swanton
Session: Poster session 14